Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation CAMP | 0.00 |
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:
CAMP) with a Overweight and raises the price target from $12 to $15.
